表紙
市場調查報告書

抗生素抗性市場:各治療藥(各病原體、治療),趨勢分析,執行、投資者、顧問指南,關注企業的完全清單(2019∼2023年)

Antibiotic Resistance Markets - Therapeutics. By Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization 2019 to 2023

出版商 Howe Sound Research 商品編碼 616480
出版日期 內容資訊 英文 327 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗生素抗性市場:各治療藥(各病原體、治療),趨勢分析,執行、投資者、顧問指南,關注企業的完全清單(2019∼2023年) Antibiotic Resistance Markets - Therapeutics. By Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization 2019 to 2023
出版日期: 2019年06月03日內容資訊: 英文 327 Pages
簡介

對抗菌劑的抗性產生新的感染,變成對目前抗生劑醫療具抗性的"超級細菌"。為了掌握這個成長市場,新的技術(及新藥)開發中。

本報告提供全球抗生素抗性市場相關調查,市場現狀及未來趨勢,成長的機會,各地區趨勢,加入此市場的主要企業的簡介相關資訊彙整。

抗生素抗藥性:策略性趨勢分析

執行,行銷,銷售,事業開發人員指南

經營顧問,投資顧問指南

第1章 簡介和市場定義

  • 大的威脅和機會
  • 機會定義
  • 手法和來源
  • 美國市場預測

第2章 動態市場概要

  • 市場參與企業:作用及影響
  • 抗菌抗性的理解
  • 新的抗生劑、技術的未來
  • 抗菌抗性中診斷的重要角色

第3章 市場機會

  • 大的市場機會
  • 治療技術開發機會
  • 近幾年的發展

第4章 生物科技企業及技術

  • 治療藥
  • 治療花邊

第5章 各國市場規模:北美

第6章 各國市場規模:歐洲

第7章 各國市場規模:亞太地區

第8章 各國市場規模:南美,非洲,中東

第9章 全球市場摘要:2017∼2023年

  • 市場摘要
    • 各病原體
    • 各技術機會

第10章 未來趨勢

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

"Search for Alternatives to Antibiotics creates new global technology race. Over 100 companies in the running...."

OVERVIEW

Antimicrobial Resistance is creating new kinds of infections and "superbugs" that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. We have identified the 6 Key Large Opportunities in this space and developed market forecasts. We have looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play. This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. And we summarize what technologies they are using.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

B.Sc. (Chemistry) University of BC

M.B.A. (Finance and Policy) University of BC

Market Research Seminar - Burke Institute

Finance for Senior Executives - Harvard Business School

Table of Contents

i. Antimicrobial Resistance - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 The Growing Threat and Opportunity of Antimicrobial Resistance
  • 1.2 Defining the Opportunity
    • 1.2.1 Revenue Market Size
  • 1.3 Methods and Sources
    • 1.3.1 Authors
    • 1.3.2 Sources
  • 1.4 U.S. Antibiotic Markets - Perspective
    • 1.4.1 U.S. Outpatient Use of Antibiotics
    • 1.4.2 U.S. Pharmaceutical Spending

2. Overview of a Dynamic Market

  • 2.1 Market Players - Roles & Impacts
    • 2.1.1 Drug manufacturers - Larger/pharmaceutical
    • 2.1.2 Drug manufacturers - Generic
    • 2.1.3 Contract Research and Manufacturing
    • 2.1.4 In Vitro Diagnostics Industry
    • 2.1.5 Drug Marketing Companies
    • 2.1.6 Biotechnology Companies
    • 2.1.7 Regulatory Bodies
  • 2.2 Understanding Antimicrobial Resistance
    • 2.2.1 What is Antimicrobial Resistance (AMR)
    • 2.2.2 Bacteria and Other Microbes
    • 2.2.3 The History of Antibiotics
    • 2.2.4 The Role of Animal Husbandry
    • 2.2.5 The Implications of Horizontal Transfer
    • 2.2.6 The Threat of AMR
  • 2.3 The Changing Road to New Antibiotics & Technologies
  • 2.4 The Key Role of Diagnostics in AMR

3. The Market Opportunity of AMR

  • 3.1 The Key Large Market Opportunities in AMR
    • 3.1.1 Streptococcus Pneumoniae (DRSP)
    • 3.1.2 Campylobacter (DRC)
    • 3.1.3 Clostridium Difficile (CD)
    • 3.1.4 Staphylococcus aureus (MRSA)
    • 3.1.5 Neisseria gonorrhoeae (DRNG)
    • 3.1.6 Salmonella (DRNTS)
  • 3.2 Therapeutic Technology Development Opportunities
    • 3.2.1 Using Viruses Against Bacteria
    • 3.2.2 Hydrolytic Enzymes Join the Fight.
    • 3.2.3 Antibodies.
    • 3.2.4 Vaccines
    • 3.2.5 Probiotic Technology
    • 3.2.6 Peptides vs. Pathogens
    • 3.2.7 Mining Obsolete Science
    • 3.2.8 CRISPR Antibiotics
  • 3.3. Antibiotic Resistance Recent Developments
    • 3.3.1 Recent Developments - Importance and How to Use This Section
    • 3.3.2 Importance of These Developments
    • 3.3.3 How to Use This Section
    • 3.3.9 CRISPR Modifies Phages to target Superbugs
    • 3.3.4 Genetically Modified Phage Fights 'Superbug' Infection
    • 3.3.5 NIH awards $33 million grant to develop new antibiotics
    • 3.3.6 Bacteria found in ancient Irish soil halts growth of superbugs
    • 3.3.7 OpGen Partners With NYS DOH, Merck Subsidiary for AMR Surveillance
    • 3.3.8 New breakthrough in the war against antibiotic resistance
    • 3.3.72 Amicrobe, Inc., patents AMR Gel
    • 3.3.73 Microneedle Patch to Combat AMR
    • 3.3.74 Antimicrobial peptides find application medium
    • 3.3.75 Antibiotic shortages fuelling antimicrobial resistance
    • 3.3.10 VenatoRx Pharmaceuticals Raises $42 Million Series B
    • 3.3.11 Wockhardt Receives Approval for Phase III Trial
    • 3.3.12 Phagelux, Inc. Announces Collaboration with Johnson & Johnson
    • 3.3.13 bioMérieux, Inc. and McKesson Medical-Surgical Announce Distribution Alliance 101
    • 3.3.14 AstraZeneca to sell antibiotics branch to Pfizer
    • 3.3.15 Microbiotix and AMR Centre Announce Co-Development Agreement
    • 3.3.16 Hennepin Life Sciences Presents Pre-Clinical Data
    • 3.3.17 bioMérieux receives FDA clearance for expanded pathogen identification capability
    • 3.3.18 Sequoia Sciences Receives FDA Fast Track Designation
    • 3.3.19 Forge Therapeutics Presents New Efficacy Data
    • 3.3.20 Acquisition Strategy Fills Out Roche's Pipeline
    • 3.3.21 Alopexx completes trial of broad-spectrum anti-microbial vaccine
    • 3.3.22 Integrated Biotherapeutics Partners with CARB-X for MRSA Vaccine
    • 3.3.23 BD Molecular Test for Infectious Diarrhea Cleared
    • 3.3.24 Fusion Genomics Developing All Pathogens Diagnostic.

4. Key Biotechnology Companies and Their Technology

  • 4.2 Therapeutics
    • 4.2.1 The Medicines Company
    • 4.2.2 Melinta Therapeutics
    • 4.2.3 Arsanis
    • 4.2.4 Phage Technologies S.A
    • 4.2.5 Westway Health
    • 4.2.6 Tetraphase Pharmaceuticals
    • 4.2.7 BioVersys GmbH
    • 4.2.8 Nabriva Therapeutics.
    • 4.2.9 Macrolide Pharmaceuticals
    • 4.2.10 Nemesis Bioscience
    • 4.2.11 C3J Therapeutics, Inc.
    • 4.2.12 EpiBiome
    • 4.2.13 discuva
    • 4.2.14 SmartPhage
    • 4.2.15 AmpliPhi Biosciences
    • 4.2.16 Pherecydes Pharma
    • 4.2.17 Micreos
    • 4.2.18 Procarta Biosystems
    • 4.2.19 Lumavita
    • 4.2.20 Madam Therapeutics
    • 4.2.21 Priaxon
    • 4.2.22 Biolytx Pharmaceuticals
    • 4.2.23 AntibioTx
    • 4.2.24 Xellia Pharmaceuticals
    • 4.2.25 Paratek Pharmaceuticals
    • 4.2.26 Synereca Pharmaceuticals
    • 4.2.27 Allecra Therapeutics
    • 4.2.28 Fixed Phage
    • 4.2.29 Enanta Pharmaceuticals, Inc.
    • 4.2.30 Demuris
    • 4.2.31 Prommune
    • 4.2.32 Biosergen
    • 4.2.33 Innovation Pharmaceuticals
    • 4.2.34 Aviragen Therapeutics
    • 4.2.35 Achillion Pharmaceuticals
    • 4.2.36 ImmunNovative Developments, S.L.
    • 4.2.37 Achaogen, Inc.
    • 4.2.38 SelectX Pharmaceuticals, Inc.
    • 4.2.39 TaiGen Biotechnology Co., Ltd.
    • 4.2.40 Theravance Biopharma
    • 4.2.41 Abbvie
    • 4.2.42 KYORIN Pharmaceutical Co.,Ltd.
    • 4.2.43 Iterum Therapeutics Limited
    • 4.2.44 Forge Therapeutics
    • 4.2.45 Alopexx Vaccine LLC
    • 4.2.46 Integrated Biotherapeutics
    • 4.2.47 Hennepin Life Sciences
    • 4.2.48 Fedora Pharmaceuticals Inc.
    • 4.2.49 Contrafect Corporation
    • 4.2.50 Basilea Pharmaceutica Ltd.
    • 4.2.51 AiCuris
    • 4.2.52 RedHill Biopharma
    • 4.2.53 Redx Pharma Plc/ Redx Anti Infectives Ltd.
    • 4.2.54 ABAC Therapeutics
    • 4.2.55 Alaxia SAS
    • 4.2.56 Antabio S.A.S
    • 4.2.57 Auspherix Ltd
    • 4.2.58 BioFilm Pharma
    • 4.2.59 Centauri Therapeutics Ltd
    • 4.2.60 Combioxin SA
    • 4.2.61 Da Volterra
    • 4.2.62 Debiopharm International SA
    • 4.2.63 Deinobiotics/Deinove
    • 4.2.64 Destiny Pharma plc
    • 4.2.65 Eligo Bioscience
    • 4.2.66 Helperby Therapeutics Ltd
    • 4.2.67 Karveel Pharmaceuticals
    • 4.2.68 MaaT Pharma
    • 4.2.69 Motif BioSciences, Inc / Motif Bio PLC
    • 4.2.70 Mutabilis SAS
    • 4.2.71 Neem Biotech Ltd
    • 4.2.72 Northern Antibiotics Oy (Ltd)
    • 4.2.73 Nosopharm
    • 4.2.74 NovaBiotics Ltd
    • 4.2.75 Phico Therapeutics Ltd
    • 4.2.76 Polyphor Ltd
    • 4.2.77 QureTech Bio AB
    • 4.2.78 SetLance srl
    • 4.2.79 Ultupharma AB
    • 4.2.80 Vaxdyn
    • 4.2.81 Vibiosphen
    • 4.2.82 Bioaster
    • 4.2.83 Vivexia
    • 4.2.85 KBP Biosciences
    • 4.2.86 Absynth Biologics
    • 4.2.87 Spero Therapeutics
    • 4.2.88 Merck
    • 4.2.89 Symphogen
    • 4.2.90 Warp Drive Bio
    • 4.2.91 Johnson & Johnson (Janssen)
    • 4.2.92 Pfizer
    • 4.2.93 Allergan
    • 4.2.95 Novartis
    • 4.2.97 AstraZeneca
    • 4.2.100 Cipla
    • 4.2.101 DSM Sinochem Pharmaceuticals
    • 4.2.102 Wockhardt Ltd.
    • 4.2.103 VenatoRx Pharmaceuticals
    • 4.2.104 MicuRx
    • 4.2.105 Entasis Therapeutics
    • 4.2.106 Merlion Pharmaceuticals
    • 4.2.107 Aridis Pharmaceuticals Inc
  • 4.3 The Therapeutics Race - Summary of Companies Research Areas

5. Country Market Sizes - North America 2017 to 2023

  • 5.1 United States of America 2017 to 2023
    • 5.1.1 USA by Pathogen
    • 5.1.2 USA by Technology Opportunity
  • 5.2 Canada 2017 to 2023
    • 5.1.1 Canada by Pathogen
    • 5.1.2 Canada by Technology Opportunity

6. Country Markets - Europe 2017 to 2023

  • 6.1 France 2017 to 2023
    • 6.1.1 France by Pathogen
    • 6.1.2 France by Technology Opportunity
  • 6.2 Germany 2017 to 2023
    • 6.2.1 Germany by Pathogen
    • 6.2.2 Germany by Technology Opportunity
  • 6.3 United Kingdom 2017 to 2023
    • 6.3.1 United Kingdom by Pathogen
    • 6.3.2 United Kingdom by Technology Opportunity
  • 6.4 Spain 2017 to 2023
    • 6.4.1 Spain by Pathogen
    • 6.4.2 Spain by Technology Opportunity
  • 6.5 Italy 2017 to 2023
    • 6.5.1 Italy by Pathogen
    • 6.5.2 Italy by Technology Opportunity
  • 6.6 Russia 2017 to 2023
    • 6.6.1 Russia by Pathogen
    • 6.6.2 Russia by Technology Opportunity
  • 6.7 Remainder of Europe and Former USSR 2017 to 2023
    • 6.7.1 Remainder of Europe and Former USSR by Pathogen
    • 6.7.2 Remainder of Europe and Former USSR by Technology Opportunity

7. Country Markets - Asia Pacific 2017 to 2023

  • 7.1 China 2017 to 2023
    • 7.1.1 China by Pathogen
    • 7.1.2 China by Technology Opportunity
  • 7.2 Japan 2017 to 2023
    • 7.2.1 Japan by Pathogen
    • 7.2.2 Japan by Technology Opportunity
  • 7.3 South Korea 2017 to 2023
    • 7.3.1 South Korea by Pathogen
    • 7.3.2 South Korea by Technology Opportunity
  • 7.4 India 2017 to 2023
    • 7.4.1 India by Pathogen
    • 7.4.2 India by Technology Opportunity
  • 7.5 Australia 2017 to 2023
    • 7.5.1 Australia by Pathogen
    • 7.5.2 Australia by Technology Opportunity
  • 7.6 Remainder of Asia Pacific 2017 to 2023
    • 7.6.1 Remainder of Asia Pacific by Pathogen
    • 7.6.2 Remainder of Asia Pacific by Technology Opportunity

8. Country Markets - Latin America, Africa & The Middle East 2017 to 2023

  • 8.1 Brazil 2017 to 2023
    • 8.1.1 Brazil by Pathogen
    • 8.1.2 Brazil by Technology Opportunity
  • 8.2 Mexico 2017 to 2023
    • 8.2.1 Mexico by Pathogen
    • 8.2.2 Mexico by Technology Opportunity
  • 8.3 Remainder of Latin America 2017 to 2023
    • 8.3.1 Remainder of Latin America by Pathogen
    • 8.3.2 Remainder of Latin America by Technology Opportunity
  • 8.4 Africa & The Middle East 2017 to 2023
    • 8.4.1 Africa & The Middle East by Pathogen
    • 8.4.2 Africa & The Middle East by Technology Opportunity

9. Global Market Summary 2017 to 2023

  • 9.1 Global Market Summary 2017 to 2023
    • 9.1.1 Global Market Summary by Pathogen
    • 9.1.2 Global Market Summary by Technology Opportunity

10. The Future of AMR

Appendices

  • I. United States Medicare System: Top Selling Drugs 2011-2015

Table of Tables

  • Table 1 USA - Outpatient Use of Antibiotics by Class
  • Table 2 USA - Outpatient Use of Antibiotics Top 5
  • Table 3 Market Players by Type
  • Table 4 Known Human Pathogenic Diseases
  • Table 5 The Key Market Opportunities
  • Table 6 - Market Potential DRSP Therapeutic
  • Table 7 - Market Potential DRC Therapeutic
  • Table 8 Eight Technologies under development
  • Table 9 Antibodies Approved for Infectious Disease Treatment
  • Table 10 Therapeutic Technology Research - # of Companies
  • Table 11 USA by Pathogen
  • Table 12 USA by Technology Opportunity
  • Table 13 Canada by Pathogen
  • Table 14 Canada by Technology Opportunity
  • Table 15 France By Pathogen
  • Table 16 France By Technology Opportunity
  • Table 17 Germany By Pathogen
  • Table 18 Germany By Technology Opportunity
  • Table 19 UK By Pathogen
  • Table 20 UK By Technology Opportunity
  • Table 21 Spain by Pathogen
  • Table 22 Spain by Technology Opportunity
  • Table 23 Italy By Pathogen
  • Table 24 Italy By Technology Opportunity
  • Table 25 Russia By Pathogen
  • Table 26 Russia By Technology Opportunity
  • Table 27 Remainder of Europe and Former USSR By Pathogen
  • Table 28 Remainder of Europe and Former USSR By Technology Opportunity
  • Table 29 China By Pathogen
  • Table 30 China By Technology Opportunity
  • Table 31 Japan By Pathogen
  • Table 32 Japan By Technology Opportunity
  • Table 33 South Korea By Pathogen
  • Table 34 South Korea By Technology Opportunity
  • Table 35 India by Pathogen
  • Table 36 India by Technology Opportunity
  • Table 37 Australia By Pathogen
  • Table 38 Australia By Technology Opportunity
  • Table 39 Remainder of Asia Pacific By Pathogen
  • Table 40 Remainder of Asia Pacific By Technology Opportunity
  • Table 41 Brazil By Pathogen
  • Table 42 Brazil By Technology Opportunity
  • Table 43 Mexico By Pathogen
  • Table 44 Mexico By Technology Opportunity
  • Table 45 Remainder of Latin America By Pathogen
  • Table 46 Remainder of Latin America By Technology Opportunity
  • Table 47 Africa & The Middle East by Pathogen
  • Table 48 Africa & The Middle East by Technology Opportunity
  • Table 49 Global Market Summary by Pathogen
  • Table 50 Global Market Summary by Technology Opportunity
  • Table 51 2011 to 2015 Top Selling Drugs

Table of Figures

  • Figure 1 Pharmaceutical Spending History by Country
  • Figure 2 AMR and Antibiotic Introduction
  • Figure 3 The Death Toll of AMR
  • Figure 4 Phage T4 Anatomy and Infection Cycle

Table of Tables

  • Table 1: USA - Outpatient Use of Antibiotics by Class
  • Table 2: USA - Outpatient Use of Antibiotics Top 5
  • Table 3: Market Players by Type
  • Table 4: Known Human Pathogenic Diseases
  • Table 5: The Key Market Opportunities
  • Table 6: Market Potential DRSP Therapeutic
  • Table 7: Market Potential DRC Therapeutic
  • Table 8: Eight Technologies under development
  • Table 9: Antibodies Approved for Infectious Disease Treatment
  • Table 10: Therapeutic Technology Research - # of Companies
  • Table 11: USA by Pathogen
  • Table 12: USA by Technology Opportunity
  • Table 13: Canada by Pathogen
  • Table 14: Canada by Technology Opportunity
  • Table 15: France By Pathogen
  • Table 16: France By Technology Opportunity
  • Table 17: Germany By Pathogen
  • Table 18: Germany By Technology Opportunity
  • Table 19: UK By Pathogen
  • Table 20: UK By Technology Opportunity
  • Table 21: Spain by Pathogen
  • Table 22: Spain by Technology Opportunity
  • Table 23: Italy By Pathogen
  • Table 24: Italy By Technology Opportunity
  • Table 25: Russia By Pathogen
  • Table 26: Russia By Technology Opportunity
  • Table 27: Remainder of Europe and Former USSR By Pathogen
  • Table 28: Remainder of Europe and Former USSR By Technology Opportunity
  • Table 29: China By Pathogen
  • Table 30: China By Technology Opportunity
  • Table 31: Japan By Pathogen
  • Table 32: Japan By Technology Opportunity
  • Table 33: South Korea By Pathogen
  • Table 34: South Korea By Technology Opportunity
  • Table 35: India by Pathogen
  • Table 36: India by Technology Opportunity
  • Table 37: Australia By Pathogen
  • Table 38: Australia By Technology Opportunity
  • Table 39: Remainder of Asia Pacific By Pathogen
  • Table 40: Remainder of Asia Pacific By Technology Opportunity
  • Table 41: Brazil By Pathogen
  • T able 4: Brazil By Technology Opportunity
  • Table 43: Mexico By Pathogen
  • Table 44: Mexico By Technology Opportunity
  • Table 45: Remainder of Latin America By Pathogen
  • Table 46: Remainder of Latin America By Technology Opportunity
  • Table 47: Africa & The Middle East by Pathogen
  • Table 48: Africa & The Middle East by Technology Opportunity
  • Table 49: Global Market Summary by Pathogen
  • Table 50: Global Market Summary by Technology Opportunity
  • Table 51: 2011 to 2015 Top Selling Drugs

Table of Figures

  • Figure 1: Pharmaceutical Spending History by Country
  • Figure 2: AMR and Antibiotic Introduction
  • Figure 3: The Death Toll of AMR
  • Figure 4: Phage T4 Anatomy and Infection Cycle
Back to Top